A 67-year-old woman was admitted to our hospital under suspicion of a hepatic tumor, which had been previously diagnosed to be an adenocarcinoma by fine needle aspiration. Computed tomography and magnetic resonance imaging revealed a large tumor measuring 9 cm in diameter in Couinaud's hepatic segments 4, 5, and 8. We diagnosed the patient to have primary liver cancer, and suspected intrahepatic cholangiocarcinoma preoperatively. We performed a central hepatectomy. According to the immunohistochemical findings of the resected specimen, the tumor was diagnosed to be a primary neuroendocrine carcinoma in the liver. The patient is presently alive without recurrence at 3 months after hepatic resection. (Korean J Hepatobiliary Pancreat Surg 2013;17:34-37)
INTRODUCTION

Primary neuroendocrine tumors develop in organs or
tissues that contain neuroendocrine cells. Most of the reported cases are carcinoid tumors. 1 Gastrointestinal tract neuroendocrine tumors often metastasize to the liver, 2 but primary neuroendocrine carcinoma in the liver is extremely rare, and there are only 22 reports of the clinical and pathologic features of primary hepatic neuroendocrine carcinoma in the English literature. 3 In addition, reports on primary hepatic neuroendocrine carcinoma are scarce in the Korea.
Primary hepatic neuroendocrine tumors are found in adults with the mean age of older than 40 years. It occurs with a slightly higher incidence in women. When symptomatic, patients present with abdominal pain and/or palpable hepatic mass. It is difficult to preoperatively differentiate primary neuroendocrine carcinomas in the liver from other solid tumors, especially hepatocellular carcinoma (HCC). Associated typical carcinoid syndrome is uncommon. Metastases to bone and lymph nodes occur more often than to lung. 4 In the present case, several examinations showed that there was no primary lesion outside the liver. We herein report a successfully resected case of a primary neuroendocrine carcinoma in the liver.
CASE
A 67-year-old woman was admitted to our department Ki-67 positive value was 40% (Fig. 2) .
To confirm that the tumor was a primary neoplasm of the chest and abdominal CT were also performed. These examinations failed to reveal a primary lesion outside the liver. Finally, we diagnosed the patient to have a primary neuroendocrine tumor in the liver and classified the cancer as a well-differentiated neuroendocrine carcinoma based on the immunohistochemical findings.
DISCUSSION
Gastrointestinal tract neuroendocrine carcinoma is often metastasized to the liver, but primary hepatic neuroendocrine carcinoma is rarely seen. Neuroendocrine carcinoma is described as a malignant epithelial neoplasm of the gastrointestinal tract with a predominantly neuroendocrine differentiated pattern that is different from carcinoid, atypical carcinoid, and adenocarcinoma with neuroendocrine differentiation. 1 The majority of neuroendocrine carcinoma cases do not have any background liver disease such as hepatitis or cirrhosis. 5 Most patients are discovered by health examination with a solid liver mass. Postoperative pathologic examination is the main method for a final diagnosis. Neuroendocrine carcinoma is diagnosed when the tumor shows diffuse cell proliferation without these typical histologic patterns. 4 Chromogranin A is considered the most useful marker to confirm neuroendocrine tumors, such as NEC and carcinoid tumors.
Chromogranin A is widely distributed in the endocrine and neuronal cells, and is cleaved to different bioactive peptides such as vasostatin, β-granin, chromostatin, and pancreastatin. 8 In the present case, chromogranin A was positive, and frequent mitotic cells and an atypical histologic pattern were observed. Therefore, the tumor was diagnosed as NEC. However, there is no consensus on the diagnostic methods that can be used to distinguish a primary NET in the liver from metastatic NET in the liver.
Until now the most effective therapy for primary hepatic neuroendocrine carcinoma is hepatectomy. The 5-year recurrence-free survival rate and overall survival rate of patients with NEC after hepatic resection was 19% and 78%, respectively, with median observation of 40 months. 
